TH Theratechnologies Inc.

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2024 ended November 30 on Wednesday, February 26, 2025, at 8:30 a.m. ET.

The call will be hosted by Paul Lévesque, President and Chief Executive Officer, who will be joined by other members of the management team, including Philippe Dubuc, Senior Vice President and Chief Financial Officer, Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer and John Leasure, Global Commercial Officer. They will be available to answer questions from participants following prepared remarks.

Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below.

CONFERENCE CALL INFORMATION
Conference Call DateFebruary 26, 2025
Conference Call Time8:30 a.m. ET
Webcast link
Dial in1-888-513-4119 (toll free) or 1-412-902-6615 (international)
Access Code4430181
CONFERENCE CALL REPLAY
Toll Free1-877-344-7529 (US) / 1-855-669-9658 (Canada)
International Toll1-412-317-0088
Replay Access Code3856571
Replay End DateMarch 5, 2025
To access the replay using an international dial-in number, please select this link: 



An archived webcast will also be available on the Company’s Investor Relations website under ‘.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at , on SEDAR+ at  and on EDGAR at . Follow Theratechnologies on  and . 

Contacts:

Investor inquiries:

Joanne Choi

Senior Director, Investor Relations



1-551-261-0401



Media inquiries:

Julie Schneiderman

Senior Director, Communications & Corporate Affairs



1-514-336-7800



EN
14/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Theratechnologies Inc.

 PRESS RELEASE

Theratechnologies présente des données de suppression virologique enco...

Theratechnologies présente des données de suppression virologique encourageantes provenant de l’essai PROMISE-US portant sur l’ibalizumab lors de la CROI Les résultats montrent des niveaux semblables de charge virale indétectable chez les patients qui reçoivent des traitements comprenant de l’ibalizumab que chez les témoins, malgré un degré de gravité initial du VIH supérieur L’ibalizumab continue de montrer son efficacité et son innocuité à long terme dans le cadre d’un traitement antirétroviral d’association chez les personnes vivant avec le VIH qui ont déjà reçu de nombreux traitement...

 PRESS RELEASE

Theratechnologies Presents Encouraging Virologic Suppression Data from...

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination antiretroviral therapy in heavily treatment-experienced people with multidrug resistant HIV MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a...

 PRESS RELEASE

Theratechnologies CROI Presentation Highlights Limitations of Using BM...

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV Study Demonstrates Excess Visceral Abdominal Fat Drives CV Risk MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today presented data highlighting the limitations of using body mass index (BMI) alone in assessing cardiovascular (CV) risk in people with HIV (PWH). The study underscores the need to incorporate screening for excess viscer...

 PRESS RELEASE

La présentation de Therachnologies lors de la CROI met en évidence les...

La présentation de Therachnologies lors de la CROI met en évidence les limites liées à l’utilisation de l’IMC pour évaluer le risque de maladie cardiovasculaire (CV) chez les personnes vivant avec le VIH Une étude montre que l’excès de graisse viscérale abdominale est associé au risque de maladie CV MONTRÉAL, 12 mars 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, a présenté aujourd’hui des données mettant en évidence les limites liées à l’utilisation de l’indice de m...

 PRESS RELEASE

Theratechnologies Reports Financial Results for the Fourth Quarter and...

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024 Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million Achieved record quarterly revenue of $25 million and annual revenue of $85.9 million New credit facilities’ favorable interest rates and amortization schedules free up approximately $19 million in cash in 2025 In-licensed two new Ionis assets in Canada to drive long-term growth MONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Therat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch